Unraveling Eosinophilic Granulomatosis With Polyangiitis (EGPA): Sharing Patients’ Perspectives to Improve Clinician Awareness, Diagnosis, and Management
Credit Amount: 1.0 AMA PRA Category 1 Credits™
Release Date: 07/01/2020
Expiration Date: 06/30/2021
Estimated Time to Complete Activity: 1.0 hours
Joint Providership Statement
This activity is jointly provided by Global Education Group and Global Academy for Medical Education
Statement of Educational Need
Many allergists, immunologists, rheumatologists, nephrologists, pulmonologists, and cardiologists are not conversant with evidence-based approaches to recognizing potential signs and symptoms of, evaluating, and diagnosing EGPA. Clinicians are also often not aware of the latest data on the efficacy, safety, and tolerability of, and candidacy criteria for, currently approved and late-stage investigational agents for EGPA. This comprehensive program provides up-to-date information regarding EGPA—its recognition, diagnosis, and treatment—and incorporates the patient perspective to raise awareness of patients’ needs, heighten urgency, and, ultimately, educate on the disease. In addition, given the nature of EGPA, a multidisciplinary approach to care is necessary to achieve optimal outcomes; however, clinicians may not be familiar with effective strategies for multidisciplinary care of patients with EGPA and, similarly, may lack the skills to engage patients with EGPA in shared decision making. This activity will include a discussion of not only the roles of members of the multidisciplinary team, but also the need for and strategies to facilitate shared decision making in the treatment of EGPA.
After completing this activity, the participant should be better able to:
- Identify signs and symptoms that may be indicative of EGPA and evidence-based approaches to evaluating and diagnosing EGPA in patients who present with those signs and symptoms.
- Summarize the latest data on the efficacy, safety, tolerability, and indications for approved and latestage investigational agents for treating the main manifestations of EGPA.
- Describe strategies for multidisciplinary collaboration and communication to optimize the comprehensive care of patients with EGPA.
Philip Seo, MD, MHS
Associate Professor of Medicine
Johns Hopkins University School of Medicine
Division of Rheumatology
Director, The Johns Hopkins Vasculitis Center
Michael E. Wechsler, MD, MMSc
Professor of Medicine
Division of Pulmonary, Critical Care and Sleep Medicine
Director, The Cohen Family Asthma Institute
National Jewish Health
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Global Academy for Medical Education. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.
This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Term of Offering
This activity was released on July 1, 2020, and is valid for one year. Requests for credit must be made no later than June 30, 2021.
Global Contact Information
For information about the accreditation of this program, please contact Global Eduction Group at 303-395-1782 or email@example.com.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Michael Wechsler, MD, MMSc: Advisor/Consultant: AstraZeneca; Equillium, Inc; Genentech; GlaxoSmithKlineplc; Novartis; Regeneron; Sanofi S. A.; Teva. Grants/ Research Support: AstraZeneca, Regeneron, Sanofi S. A.
Philip Seo, MD, MHS: Advisor/Consultant: GlaxoSmithKline The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Global Education Group: The following planners and managers Lindsay Borvansky; Ashley Cann; Andrea Funk; Liddy Knight; and Ashley Marostica, RN, MSN, have nothing to disclose.
Global Academy for Medical Education/Medscape: Catherine Friederich Murray, MNLM, and Tom Garry have nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Global Academy for Medical Education do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Questions About the Activity
For information about the accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.
Computer System Requirements
Internet Explorer 9.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above